Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$7.44 USD
-0.11 (-1.46%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.41 -0.03 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Mesoblast Limited [MESO]
Reports for Purchase
Showing records 81 - 91 ( 91 total )
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Realizing the Promise of Stem Cell Therapy; Assuming Coverage With a Buy and $6.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Phase 2b LVAD Results Offer Potential for Regulatory Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Mesoblast Expands Its Relationship With JCR Pharma in Japan
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Late Breaker at the American Heart Association (AHA) in Chicago
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
180-Day Data for A-GvHD Trial Is Positive; Lays Groundwork for First Product Launch in 2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Mesoblast and Tasly Announce Chinese Government Approval for the Deal to Proceed
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
A Year of Cash and Catalysts; Data Possible at the American Heart Association
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Mesoblast Strikes a $40M Upfront Deal With Tasly Pharmaceuticals for Cardiovascular Therapy in China
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Mesoblast Picks up $50M in Additional Funding on Good Terms for Remestemcel-L (GvHD)
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Top Line 100 Day Results in GvHD Show a 75% Overall Survival Rate
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Multiple Trials in LVAD,CHF, CLBP and GvHD Are Drivers; Initiating With Buy and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J